Careers  |  Sign In  |  Register
Changing Paradigms in Targeted MS Therapies: Examining New Evidence on B-cell Targeted Treatments
Course List
  • CME Front Matter

Downloadable Education Resources

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Target Audience

The intended audience for the activity is neurologists and other health care professionals involved in the treatment of patients with multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Apply new clinical data about the mechanisms of action, safety, and efficacy of emerging targeted approaches for the treatment of multiple sclerosis.

  • Evaluate the latest evidence about current and investigational treatment options for progressive multiple sclerosis.

Activity Chair

Patricia K. Coyle, MD, FAAN
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Multiple Sclerosis Comprehensive Care Center at Stony Brook University Medical Center
Stony Brook, NY


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™, 0.25 credits per video. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, April 2, 2015 to April 1, 2016.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Planning Committee and Faculty

Patricia K. Coyle, MD, FAAN


Bruce A. Cohen, MD
Ronald A. Codario, MD, FACP, CCMEP


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.

  • Planning Committee and Faculty members report the following relationship(s):

    • Patricia K. Coyle, MD, FAAN
      • Consulting Fee: AbbVie, Accordant, Acorda Therapeutics, Bayer, Biogen, Genentech/Roche, Genzyme/Sanofi, Mylan, Novartis, Serono, Teva Neuroscience
      • Contracted Research: Actelion, Novartis, Opexa

  • Reviewers report the following relationship(s):

    • Bruce A. Cohen, MD
      • Consulting Fee: Acorda Therapeutics, EMD Serono, Genentech, Genzyme, Novartis, Questcor, Teva Neuroscience

    • Ronald A. Codario, MD, FACP, CCMEP
      • No relevant financial relationships to disclose

  • Vindico Medical Education staff report the following relationship(s):
    • No relevant financial relationships to disclose

  • Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Treatment with disease modifying therapies (DMTs) can transform the otherwise debilitating course of multiple sclerosis (MS), a progressive, inflammatory, autoimmune disease of the central nervous system. For patients with established disease, DMTs are directed toward reducing the frequency and severity of clinical attacks, slowing the progression of disability, and reducing accumulation of lesions within the brain and spinal cord. Over the last several decades, treatment options have been developed for their effect on T cells in the pathogenesis of MS. However, recent evidence has shown that B cells and humoral immunity also play a key role in MS pathogenesis, which is opening the door to new treatment options. With an expansive body of evidence and new therapies emerging, it is critical that clinicians be well-versed in emerging safety, efficacy, and tolerability data associated with existing and investigational agents. This activity will explore new findings in MS pathology and treatment, and also discuss notable differences in the disease and management of patients with progressive forms of MS.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2015 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


Contact us at